

# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

## Categories:

### A. Fungitell® Diagnostic Performance

### B. (1→3)-β-D-Glucan Kinetics

### C. (1→3)-β-D-Glucan & Galactomannan: Relative Diagnostic Performance

### D. (1→3)-β-D-Glucan Meta-Analyses

### E. (1→3)-β-D-Glucan Reagent-Related

### F. Clinical Guideline-Related

### G. Clinical Mycology Reviews

### H. Miscellaneous

## A. Fungitell® Diagnostic Performance

1. Agnelli, V., Bouza, E., Martínez-Jiménez, M., Navarro, R., Valerio, M. Clinical Relevance and Prognostic Value of Persistently Negative (1→3)-β-D-Glucan in Adults with Candidemia: a 5-year experience in a tertiary hospital. *Clinical Infectious Diseases*, ciz555, <https://doi.org/10.1093/cid/ciz555>.
2. Alexander, B.D., Smith, P.B., Davis, R.D., Perfect, J.R., Reller, L.B., (2010). The (1→3)-β-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. *J. Clin. Microbiol.* 48: 4083-8.
3. Bellanger, A.P., Grenouillet, F., Henon, T., Skana, F., Legrand, F., Deconinck, E., Millon, L., (2011). Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections. *APMIS*. 119:280-6.
4. Ceasay, M.M., Desai, S.R., Berry, L., Cleverley, J., Kibbler, C.C., Pomplun, S., Nicholson, A.G., Douiri, A., Wade, J., Smith, M., Mufti, G.J., and Pagliuca, A., (2015). A comprehensive diagnostic approach using galactomannan, targeted β-D-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. *Br. J. Haematol.* 168:219-29.
5. Chowdhary, A., Randhawa, H.S., Singh, V., Khan, Z.U., Ahmad, S., Kathuria, S., Roy, P., Khanna, G., Chandra, J., (2011). *Bipolaris hawaiiensis* as etiologic agent of allergic bronchopulmonary mycosis: first case in a paediatric patient. *Med. Mycol.* 49:760-5. C101.
6. Corsi-Vasquez G, Ostrosky-Zeichner L, Pilkington EF 3rd, Sax PE. Point-Counterpoint: Should serum β-D-glucan testing be used for the diagnosis of *Pneumocystis jirovecii* pneumonia? *J Clin Microbiol.* 2019 Aug 21. pii: JCM.01340-19. doi: 10.1128/JCM.01340-19. [Epub ahead of print] PubMed [citation] PMID: 31434728
7. Cuétara, M.S., Alhambra, A., Moragues, M.D., Gonzalez-Elorza, E., Pontón, J., and Del Palacio, A. (2009). Detection of (1→3)-β-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven fungal diseases or unusual clinical presentation. *Clin. Vacc. Immunol.* 16: 423-426.
8. Damiani, C., et al., (2013). Combined Quantification of Pulmonary *Pneumocystis jirovecii* DNA and Serum (1→3)-β-D-Glucan for Differential Diagnosis of *Pneumocystis* Pneumonia and *Pneumocystis* Colonization. *J. Clin. Micro.* 51: 3380-3388.
9. De Pascale, G., Posteraro, B., Cutuli, S.L., Caricato, A., Lepore, D., Tumbarello, M., Pennisi, M.A., Sanguinetti, M., and Antonelli, M. (2013). Why should we monitor (1→3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist! *J. Clin. Microbiol.* 51:1645-6.
10. De Vlieger, G., Lagrou, K., Maertens, J., Verbeke, E., Meersseman, W., Van Wijngaerden, E., (2011). β-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study. *J. Clin. Microbiol.* 49:3783-7.
11. Del Bono, V., Mularoni, A., Furfaro, E., Delfino, E., Rosasco, L., Miletich, F., and Viscoli, C., (2009). clinical evaluation of (1→3)-β-D-Glucan assay in presumptive *Pneumocystis jirovecii* pneumonia in immunocompromised patients. *Clin. Vacc. Immunol.* 16: 1524-1526.
12. Del Bono, V., Delfino, E., Furfaro, E., Mikulska, M., Nicco, E., Bruzzi, P., Mularoni, A., Bassetti, M., Viscoli, C., (2011). Clinical Performance of the (1→3)-β-D-Glucan Assay in Early Diagnosis of Nosocomial *Candida* Bloodstream Infections. (2011). *Clin. Vaccine Immunol.* 18:2113-7.
13. Del Palacio, A., Llenas-García, J., Soledad Cuétara, M., Pulido, F., Rubio, R., Pontón, J., Del Palacio-Pérez-Medel, A., (2010). Serum (1→3)-β-D-Glucan as a noninvasive adjunct marker for the diagnosis and follow-up of *Pneumocystis jirovecii* pneumonia in patients with HIV infection. *Clin. Infect. Dis.* 50:451-2.
14. Desmet, S., Van Wijngaerden, E., Maertens, J., Verhaegen, J., Verbeke, E., De Munter, P., Meersseman, W., Van Meensel, B., Van Eldere, J., Lagrou, K., (2009). Serum (1→3)-β-D-glucan as a tool for diagnosis of *Pneumocystis jirovecii* pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. *J. Clin. Microbiol.* 47:3871-4.
15. Desoubeaux G, Chesnay A, Mercier V, Bras-Cachinho J, Moshiri P, Ymieux S, De Kyon MA, Lemaigen A, Goudeau A, Bailly É. Combination of β-(1,3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of *Pneumocystis jirovecii* pneumonia. *Mycoses.* 2019 Sep 8. doi: 10.1111/myc.12997. [Epub ahead of print] PubMed [citation] PMID: 31494981
16. Digby, J., Kalbfleisch, J., Glenn, A., Larsen, A., Browder, W. and Williams, D. (2003). Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. *Clin. Diagn. Laboratory. Immunol.* 10: 802-805.
17. Duffner, U., Abdel-Mageed, A., Dahl, K., Fogg, G. and Hester, J. (2012). Serum (1→3)-β-D-glucan levels (Fungitell® assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. *Bone Marrow Transpl.* 47: 151–152.
18. Edathodou, J., et al., (2013) Invasive fungal infection due to *Triadelpia pulvinata* in a patient with acute myeloid leukemia. *J. Clin. Microbiol.* 51:3426–9.
19. Egan, L., Connolly, P., Wheat, L. J., Fuller, D., Davis, T. E., Knox, K. S. and Hage, C. A. (2007). Histoplasmosis as a cause for a positive Fungitell® (1→3)-β-D-glucan test, *Medical Mycology*, 46:1,93–95.
20. Eggimann, P., Marchetti, O., (2011). Is (1→3)-β-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? *Crit. Care.* 15:1017.
21. Ellis, M., Ramadi, B., Finkelman, M., Hedstrom, U., Kristenson, J., Ali-Zadeh, H., and Klingspor, L., (2007). Assessment of the clinical utility of serial β-D-glucan concentrations in patients with persistent neutropenic fever. *J. Med. Microbiol.* 57: 287-95.
22. Esteves, F., et al., (2014). (1→3)-β-D-glucan in association with lactate dehydrogenase as biomarkers of *Pneumocystis* pneumonia (PCP) in HIV-infected patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 33:1173–1180.
23. Fernandez-Silva, F., et al., (2014). Experimental murine acromoniosis: an emerging opportunistic human infection. *Med. Mycol.* 52: 29-35.
24. Giacobbe, D.R., Mikulska, M., Tumbarello, M., Furfaro, E., Spadaro, M., Losito, A.R., Mesini, A., De Pascale, G., Marchese, A., Bruzzone, M., Pelosi, P., Mussap, M., Molin, A., Antonelli, M., Posteraro, B., Sanguinetti, M., Viscoli, C., and Del Bono, V.; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). (2017). Combined use of serum (1→3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. *Crit. Care.* 21:176.



# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

25. Ginocchio, F., et al., (2012). Case report of the reliability of (1→3)-β-D-glucan monitoring during the treatment of peritoneal candidiasis in a child receiving continuous peritoneal dialysis. Clin. Vacc. Immunol. 19: 626-7.
26. Girouard, G., Lachance, C., Pelletier, R., (2007). Observations on (1→3)-β-D-glucan detection as a diagnostic tool in endemic mycosis caused by *Histoplasma* or *Blastomyces*. J. Med. Microbiol. 56:1001-2.
27. Gonzales, B.E., Faverio, L.A., Marty, F.M., MacArthur, C. and Churchill, R.B., (2011). Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for *Pneumocystis jirovecii* pneumonia. Clin. Vacc. Immunol. 18: 1202–1203.
28. Goudjil, S., et al., (2013). (1→3)-β-D-glucan levels in candidiasis infections in the critically ill neonate. J. Maternal-Fetal & Neonatal Med. 26:44-8.
29. Guo J, Wu Y, Lai W, Lu W, Mu X. The diagnostic value of (1→3)-β-D-glucan alone or combined with traditional inflammatory markers in neonatal invasive candidiasis. BMC Infect Dis. 2019 Aug 14;19(1):716. doi: 10.1186/s12879-019-4364-x. PubMed [citation] PMID: 31412796, PMCID: PMC6692940
30. Hammarström, H., Kondori, N., Friman, V., and Wennerås, C. (2015). How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J. Clin. Microbiol Infect Dis. 34:917-25.
31. Hanson, K.E. et al., (2012). β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: A randomized pilot study. PLoS One 7: e42282.
32. Held, J., Koch, M., Reischl, U., Danner, T., Serr, A., (2011). Serum (1→3)-β-D-Glucan measurement as early indicator for *Pneumocystis jirovecii* pneumonia and evaluation of its prognostic value. Clin. Microbiol. Infect. 17: 595-602.
33. Held, J., et al., (2013). Comparison of (1→3)-β-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec *Candida* antigen as serum biomarkers for Candidemia. J. Clin. Micro. 51:1158-1164.
34. Heyland, D., Jiang, X., Day, A.G. and Laverdiere, M., (2011). Serum β-D-glucan of critically ill patients with suspected ventilator-associated pneumonia: Preliminary observations. J. Crit. Care. 5: 536.e1-536.e9.
35. Hoarau, G., et al., (2013). Detection of (1→3)-β-D-glucans in situ in a *Candida albicans* brain granuloma. J. Infect. 67: 622-4.
36. Kocmanová, I., Ráčil, Z., Koukalová, D., Mayer, J., (2008). (1→3)-β-D-glucan measurement and its usefulness in the diagnosis of invasive fungal infections. Klin. Mikrobiol. Infekc. Lek. 14:88-92.
37. Koo, S., Bryar, J.M., Page, J.H., Baden, L.R., and Marty, F.M., (2009). Diagnostic performance of the (1→3)-β-D-glucan assay for invasive fungal disease. Clin. Infect. Dis. 49:1650-9.
38. Lengerova, M., Kocmanova, I., Racil, Z., Hrcirova, K., Pospisilova, S., Mayer, J., Najvar, L.K., Wiederhold, N.P., Kirkpatrick, W.R., Patterson, T.F., (2012). Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1→3)-β-D-glucan detection. J. Clin. Microbiol. 50:602-8.
39. Lobo, M.L., Esteves, F., de Sousa, B., Cardoso, F., Cushion, M.T., Antunes, F., Matos, O., (2013). Therapeutic potential of caspofungin combined with trimethoprim sulfamethoxazole for *Pneumocystis pneumonia*: a pilot study in mice. PLoS One.8(8):e70619. doi: 10.1371/journal.pone.0070619.
40. Mackay, C.A., Ballot, D.E., Perovic, O., (2011). Serum (1→3)-β-D-Glucan assay in the diagnosis of invasive fungal disease in neonates. Pediatr Rep. 16;3:e14.
41. Marty, F. M., Koo, S., Bryar, and J., and Baden, L.R., (2007). (1→3)-β-D-glucan assay positivity in patients with *Pneumocystis (carinii) jirovecii* pneumonia. Ann. Int. Med. 147: 70-72.
42. Marty, F. M. and Koo, S., (2008). Role of (1→3)-β-D-Glucan in the diagnosis of invasive aspergillosis. Medical Mycology 47: Suppl. 1: S233-240
43. Mennink-Kersten, M.A., Ruegebrink, D., Wasei, N., Melchers, W.J. and Verweij, P.E., (2006). In vitro release by *Aspergillus fumigatus* of galactofuranose antigens, (1→3)-β-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J. Clin. Microbiol. 44:1711-8.
44. Metan, G., Agkus C., Buldu, H., Koç, A.N., (2010). The interaction between piperacillin/tazobactam and assays for *Aspergillus* galactomannan and (1→3)-β-D-glucan in patients without risk factors for invasive fungal infections. Infection. 38:217-21.
45. Metan, G., Agkus, C., Koç, A.N., Elmali, F., Finkelman, M.A., (2011). Does ampicillin-sulbactam cause false positivity of (1→3)-β-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses. 55: 366-71.
46. Metan, G., Koç, A.N., Atalay, A., Kaynar, L.G., Ozturk, A., Alp, E., Eser B., (2012). What should be the optimal cut-off of serum (1→3)-β-D-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies? Scand. J. Infect. Dis. 44:330-6.
47. Metan, G., Koç, A.N., Agkus, C., Kaynar, L.G., Alp, E., Eser, B., (2012). Can bacteraemia lead to false positive results in (1→3)-β-D-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev. Iberoam Micol. 29:169-71.
48. Metan, G., Koç, A.N., Kaynar, L.G., Atalay, A., Oztürk, A., Eser, B., Cetin, M., (2013). What is the role of the (1→3)-β-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses. 56:34-8.
49. Mokaddas, E., Khan, Z.U., Ahmad, S., Nampoory, M.R., Burhamah, M., (2011). Value of (1→3)-β-D-glucan, *Candida* mannan and *Candida* DNA detection in the diagnosis of candidaemia. Clin. Microbiol. Infect. 17:1549-53.
50. Montagna, M.T., Coretti, C., Lovero, G., De Giglio, O., Montagna, O., Laforgia, N., Santoro, N., Caggiano, G., (2011). Diagnostic Performance of (1→3)-β-D-Glucan in Neonatal and Pediatric Patients with Candidemia. Int. J. Mol. Sci. 12:5871-7.
51. Mohr, J.F., Sims, C., Paetznick, V., Rodriguez, J., Finkelman, M.A., Rex, J.H., and Ostrosky-Zeichner, L., (2011). A prospective survey of (1→3)-β-D-glucan and its relationship to Invasive candidiasis in the surgical ICU setting. J. Clin. Microbiol. 49: 58-61.
52. Nucci, M., Nouér, S.A., Esteves, P., Guimarães, T., Breda, G., de Miranda, B.G., Queiroz-Telles, F., and Colombo, A.L. (2016) Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-D-glucan. J Antimicrob Chemother. 71:2628-33.
53. Pang, Y.K., Ip, M., You, J.H., (2017). Potential clinical and economic outcomes of active β-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis. Eur. J. Clin. Microbiol. Infect. Dis. 36:187-194.
54. Mularoni, A., Furfaro, E., Faraci, M., Franceschi, A., Mezzano, P., Bandettini, R., Viscoli, C., and Castagnola, E., (2010). High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin. Vaccine Immunol. 17:882-3.
55. Obayashi, T., Negishi, K., Suzuki, T. and Funata, N., (2008). Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin. Infect. Dis. 46: 1864-1870.
56. Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R., Ketchum, P., Finkelman, M., Rex, J. and Ostrosky-Zeichner, L., (2004). β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clin. Inf. Dis. 39:199-205.



Reference List Publish Date:  
September 2019

Corporate Headquarters  
Associates of Cape Cod, Inc.  
124 Bernard E. Saint Jean Drive  
East Falmouth, MA 02536 USA  
Tel: (508) 540-3444  
www.acciusa.com

United Kingdom  
Associates of Cape Cod Int'l., Inc.  
Deacon Park, Moorgate Road  
Knowsley, Liverpool L33 7RX  
United Kingdom  
Tel: (44) 151-547-7444  
www.acciuk.co.uk

Europe  
Associates of Cape Cod Europe, Inc.  
Opelstrasse 14  
D-64546 Mörfelden-Walldorf  
Germany  
Tel: (49) 61 05-96 10 0  
www.acciusa.de

Page 2

MKT#19-018

# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

57. Odabasi, Z., Paetznick, V.L., Rodriguez, J.R., Chen, E., McGinnis, M.R. and Ostrosky-Zeichner, L., (2006). Differences in beta-glucan levels in culture supernatants of a variety of fungi. *Med. Mycol.* 44:267-72.
58. Ostrosky-Zeichner, L., Alexander, B.D., Kett, D.H., Vazquez, J., Pappas, P.G., Saeki, F., Ketchum, P.A., Wingard, J., Schiff, R., Tamura, H., Finkelman, M.A. and Rex, J.H., (2005). Multicenter clinical evaluation of the (1→3)-β-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clin. Inf. Dis.* 41: 299-305.
59. Ostrosky-Zeichner, L., Paetznick, V.L., Rodriguez, J., Chen, E. and Sheehan, D.J., (2009). Activity of anidulafungin in a murine model of *Candida krusei* infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1→3)-β-D-glucan levels. *Antimicrob. Agents Chemother.* 53: 1639-1641.
60. Ostrosky-Zeichner, L., et al., (2014) MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in high risk adults in the critical care setting. *Clin. Infect. Dis.* 58:1219-26.
61. Pazos, C., Ponton, J. and Del Palacio, A., (2005). Contribution of (1→3)-β-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: A comparison with serial screening for circulating galactomannan. *Journal of Clinical Microbiology* 43: 299-305.
62. Pazos, C., Moragues, M.D., Quindos, G. and del Palacio, A., (2006). Diagnostic potential of (1→3)-β-D-glucan and anti-*Candida albicans* germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. *Rev. Iberoam Micol.* 23: 209-215.
63. Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S. and Sulahian, A., (2008). Contribution of the (1→3)-β-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections. *J. Clin. Micro.* 36: 1009-1013.
64. Pickering, J.W., Sant, H.W., Bowles, C.A., Roberts, W.L. and Woods, G.L., (2005). Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. *J. Clin. Microbiol.* 43:5957-62.
65. Piscuilli, M.L. and Sax, P.E., (2008). Use of a Serum β-D-Glucan Assay for Diagnosis of HIV-Related *Pneumocystis jirovecii* Pneumonia in Patients with Negative Microscopic Examination Results. *Clin. Infect. Dis.* 46: 1928-1930.
66. Posteraro, B., De Pascale, G., Tumbarello, M., Torelli, R., Pennisi, M.A., Bello, G., Maviglia, R., Fadda, G., Sanguinetti, M., Antonelli, M., (2011). Early diagnosis of Candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, *Candida* score, and colonization index. *Crit. Care.* 22;15:R249.
67. Posteraro, B., Tumbarello, M., De Pascale, G., Liberto, E., Vallecocchia, M.S., De Carolis, E., Di Gravio, V., Treccarichi, E.M., Sanguinetti, M., and Antonelli, M. (2016). (1→3)-β-D-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. *J Antimicrob Chemother.* 71:2262-9.
68. Prattes, J., Hoenigl, M., Rabensteiner, J., Raggam, R.B., Pruellner, F., Zollner-Schwetz, I., Valentin, T., Hönlgl, K., Fruhwald, S., and Krause, R. (2014). Serum (1→3)-β-D-glucan for antifungal treatment stratification at the intensive care unit and the influence of surgery. *Mycoses.* 57:679-86.
69. Prattes, J., Raggam, R.B., Vanstraelen, K., Rabensteiner, J., Hoegenauer, C., Krause, R., Prüller, F., Wölfler, A., Spriet, I., and Hoenigl, M. (2016). Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum (1→3)-β-D-Glucan Levels? *J. Clin. Microbiol.* 54:798-801.
70. Rácil, Z., Kocmanová, I., Weinbergerová, B., Winterová, J., Lengerová, M., Hrnčířová, K., Mayer, J., (2009). Detection of (1→3)-β-D-glucan for diagnosis of invasive fungal infections in hemato-oncological patients: usefulness for screening of invasive mycosis and for confirmation of galactomannan positive results]. *Klin. Mikrobiol. Infekc. Lek.* 15:48-57.
71. Rácil, Z., Kocmanová, I., Lengerová, M., Weinbergerová, B., Buresová, L., Toskova, M., Winterová, J., Timilsina, S., Rodriguez, I., Mayer, J., (2010). Difficulties in using (1→3)-β-D-glucan as the screening test for the early diagnosis of invasive fungal diseases in patients with hematological malignancies - high frequency of false positive results and their analysis. *J. Med. Microbiol.* 59:1016-22.
72. Rácil, Z., Kocmanová, I., Toskova, M., Winterová, J., Lengerová, M., Timilsina, S., Mayer, J., (2013). Reactivity of the (1→3)-β-D-glucan assay during bacteraemia: limited evidence from a prospective study. *Mycoses.* 56:101-4.
73. Raggam, R.B., Fischbach, LM., Prattes, J., Duettmann, W., Eigl, S., Reischies, F., Wölfler, A., Rabensteiner, J., Pruellner, F., Krause, R., and Hoenigl, M. (2015). Detection of (1→3)-β-D-glucan in same-day urine and serum samples obtained from patients with hematological malignancies. *Mycoses.* 58:394-8.
74. Rautemaa, V., Green, H.D., Jones, A.M., and Rautemaa-Richardson, R. (2017). High level of β-(1,3)-D-glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease. *Diagn. Microbiol. Infect. Dis.* 88:316-321.
75. Rouzé, A., Loridant, S., Poissy, J., Dervaux, B., Sendid, B., Cornu, M., and Nseir, S.; S-TAFE study group. (2017). Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. *Intensive Care Med.* 2017 Sep 22. doi: 10.1007/s00134-017-4932-8.
76. Sax, P.E., Komarow, L., Finkelman, M., Grant, P.M., Andersen, J., Scully, E., Powderly, W.G. and Zolopa, A.R., for the AIDS Clinical Trials Group Study A5164 Team., (2011). Blood (1→3)-β-D-Glucan as a diagnostic test for HIV-related *Pneumocystis jirovecii* pneumonia. *Clin. Inf. Dis.* 53:197-202.
77. Smith, P.B., Benjamin, D.K., Alexander, B.D., Johnson, M.D., Finkelman, M.A. and Steinbach, W.J., (2007). (1→3)-β-D-Glucan levels in pediatric patients: Preliminary data for the use of the beta-glucan test in children. *Clin. Vaccine Immunol.* 14: 924-925.
78. Tissot, F., et al., (2013). Beta-Glucan antigenemia anticipates diagnosis of blood culture-negative intra-abdominal candidiasis. *Am. J. Resp. Crit. Care Med.* 188:1100-9.
79. Wiederhold, N.P., Najjar, L.K., Vallor, A.C., Kirkpatrick, W.R., Bocanegra, R., Molian, D., Olivo, M., Graybill, J.R. and Patterson, T.F., (2008). Assessment of (1→3)-β-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. *Antimicrob. Agents Chemother.* 52; 1176-1178.
80. Wood, B.R., et al., (2013). Test performance of blood beta-glucan for *Pneumocystis jirovecii* pneumonia in patients with AIDS and respiratory symptoms. *AIDS* 27: 967-972.
81. Yoshida, K., et al., (2011). Clinical viability of Fungitell®, a new (1→3)-β-D-glucan measurement kit, for diagnosis of invasive fungal infection, and comparison with other kits available in Japan. *J. Infect. Chemother.* 17: 473-477.

## B. (1→3)-β-D-Glucan Kinetics

1. Hachem, R.Y., Kontoyiannis, D.P., Chemaly, R.F., Jiang, Y., Reitzel, R. and Raad, I., (2008). Utility of galactomannan enzyme immunoassay and (1→3)-β-D-glucan in diagnosis of invasive fungal infections: low sensitivity for *Aspergillus fumigatus* infection in hematologic malignancy patients. *J. Clin. Micro.* 47: 129-133.



# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

2. Held, J. and Wagner, D., (2011). β-D-Glucan kinetics for the assessment of treatment response in *Pneumocystis jirovecii* pneumonia. Clin. Microbiol. Infect. 17: 1118-1122.
3. Jaijakul, S., et al., (2012). (1→3)-β-D-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin. Inf. Dis. 55: 521-526.
4. Koo, S., et al., (2012). Post-diagnosis kinetics of the (1→3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis, and *Pneumocystis jirovecii* pneumonia. Clin. Microbiol. Infect. 18:E122-127.
5. Mikulska, M., Furfaro, E., Del Bono, V., Gualandi, F., Van Lint, M.T., Miletich, F., Bacigalupo, A. and Viscoli, C., (2011). Persistence of positive (1,3)-beta-glucan test after clearance of candidemia in HSCT recipients. Clin. Vacc. Immunol. 18: 518-519.
6. Sims, C.R., et al., (2012). Correlation of clinical outcomes with β-glucan levels in patients with invasive candidiasis. J. Clin. Microbiol. 50:2104-2106.

## C. (1→3)-β-D-Glucan & Galactomannan Diagnostic Performance

1. Acosta J., Catalan M., Del Palacio-Pérez-Medel A., Montejo J.C., De-La-Cruz-Bértolo J., Moragues MD, Pontón J., Finkelman M.A., Del Palacio A., (2011). Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1→3)-β-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur. J. Clin. Microbiol. Infect. Dis. 31:721-31.
2. Acosta, J., Catalan, M., Del Palacio-Peréz-Medel, A., Lora, D., Montejo, J.C., Cuetara, M.S., Moragues, M.D., Ponton, J., Del Palacio, A., (2011). A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: Comparison with the diagnostic performance of galactomannan and of (1→3)-β-D-glucan chromogenic assay in serum samples. Clin. Microbiol. Infect. 17:1053-60.
3. Ahmad, S., Khan, Z.U. and Theyyathel, A.M., (2007). Diagnostic value of DNA, (1→3)-β-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Aspergillus terreus*. Diagn. Microbiol Infect. Dis. 59:165-71.
4. Ates, O., Metan, G., Dundar, T., Kiziltepe, M., Kocyigit, I., Unal, A., Sipahioğlu, M., Oymak, O., Tokgoz, B., (2013). Diagnosis of *Aspergillus niger* peritonitis in a peritoneal dialysis patient by peritoneal galactomannan and β-D-glucan detection. Perit. Dial. Int. 33:216-8.
5. Fontana, C., et al., (2012). (1→3)-β-D-glucan vs. galactomannan antigen in diagnosing invasive fungal infections. Open Microbiology Journal 6: 70-73.
6. Mosquera, R.A., Estrada, L., Clements, R.M., Jon, C.K., (2013). Early diagnosis and treatment of invasive pulmonary aspergillosis in a patient with cystic fibrosis. BMJ Case Rep. 18;2013. pii: bcr2013201360. doi: 10.1136/bcr-2013-201360.
7. Rafailidis, P.I., Falagas, M.E., Khan, Z.U., Ahmad, S., Mokaddas, E., Said, T., Nair, M.P., Halim, M.A., Nampoory, M.R. and McGinnis, M.R., (2007). Cerebral aspergillosis diagnosed by detection of *Aspergillus flavus*-specific DNA, galactomannan and (1→3)-β-D-glucan in clinical specimens. J. Med. Microbiol. 56:129-32.
8. Thornton, C.R., (2008). Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin. Vaccine Immunol. 15:1095-105.

## D. (1→3)-β-D-Glucan Meta-Analyses

1. Karageorgopoulos, D.E., Vouloumanou, E.V., Ntziora, F., Michalopoulos, A., (2011). β-D-Glucan assay for the diagnosis of invasive fungal infections: A meta-analysis. Clin. Inf. Dis. 52: 750-770.

2. Karageorgopoulos, D.E., et al., (2013). Accuracy of β-D-glucan for the diagnosis of *Pneumocystis jirovecii* pneumonia; a meta-analysis. Clin. Microbiol. Infect. 19:39-49.
3. Lamoth, F., et al., (2012). β-Glucan Antigenemia Assay for the Diagnosis of Invasive Fungal Infections in Patients With Hematological Malignancies: A Systematic Review and Meta-Analysis of Cohort Studies From the Third European Conference on Infections in Leukemia (ECIL-3). Clin. Infect. Dis. 54:633-43.

## E. (1→3)-β-D-Glucan Reagent-Related

1. Alonso, R., et al., Alzheimer's disease and disseminated mycoses. (2014). Eur. J. Microbiol. Infect. Dis. 32: 795-801.
2. Bassetti, M. and Bouza, E. (2017). Invasive mould infections in the ICU setting: complexities and solutions. J. Antimicrob Chemother. 72(suppl\_1): Review.
3. De Pauw, B. et al., (2008) Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect Dis. 15;46:1813-21.
4. Finkelman, M.A. and Tamura, H., (2005). Detection and measurement of (1→3)-β-D-glucan. In "Toxicology of (1→3)-β-D-Glucans," Young, S.H. and Castranova, V, eds. CRC Press, New York.
5. Issa, N.C., Koo S., Lynch R.C., Gay, C., Hammond, S.P., Baden, L.R., Ghobrial, I.M., Finkelman, M.A., Marty, F.M., (2011). Serum Galactomannan and (1→3)-β-D-Glucan Assays in Patients with Multiple Myeloma and Waldenström's Macroglobulinemia. J. Clin. Microbiol. 50: 1054-1056.
6. Marty, F.M., Lowry, C.M., Lempitski, S.J., Kubiak, D.W., Finkelman, M.A., and Baden, L. R., (2006) Reactivity of (1→3)-β-D-Glucan assay with commonly used intravenous antimicrobials. Antimicrob. Agents Chemo. 50: 3450-3453.

## F. Clinical Guideline-Related

1. Kullberg, B.J. et al., (2011). European Expert opinion on the management of invasive candidiasis in adults. Clin. Microbiol. Infect. Suppl. 5: 1-12.
2. Lortholary, O. et al., (2012) ESCMID\* guideline for the diagnosis and management of *Candida* diseases 2012: diagnostic procedures. Clin. Microbiol. Infect; 18 (Suppl. 7): 9-18.
3. Maschmeyer, G., et al., (2015). Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): Updated guidelines of the infectious diseases working party of the German Society of Haematology and Oncology (DGHO). Ann Oncol. 2015;26:21-33.
4. Marchetti, O., Lamoth, F., Mikulska, M., Viscoli, C., Verweij, P., Bretagne, S., (2011). ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 47: 846-54.
5. Rhunke, M. et al., (2012). Diagnosis of invasive fungal infections in hematology and oncology guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol. 23:823-33.
6. Rhodes, A., Evans, L.E., Alhazzani, W. et al., (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 43:304-377.
7. Segal, B.H. et al., (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study



# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Inf. Dis. 47:674-683.

## G. Clinical Mycology Reviews

1. Fisher, B.T., (2013). The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children. Curr. Fungal Infect Rep. 7:7-14.
2. Finkelman, M.A., (2010). *Pneumocystis jirovecii* infection: Cell wall (1→3)-β-D-glucan: Biology and diagnostic utility. Crit. Rev. Microbiol. 36: 271-81.
3. Ponton, J., (2009). Usefulness of biological markers in the diagnosis of invasive candidiasis. Rev. Iberoam. Micol. 26:8-14.

## H. Miscellaneous

1. Carr A, Colley P, Berhe M, Nguyen HL. Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin. Proc (Bayl Univ Med Cent). 2018 Jan 2;31(1):30-34. doi: 10.1080/08998280.2017.1396164. eCollection 2018 Jan. Erratum in: Proc (Bayl Univ Med Cent). 2019 Apr 23;32(2):324. PubMed [citation] PMID: 29686548, PMCID: PMC5903500.
2. Chibabhai V, Fadana V, Bosman N, Nana T. Comparative sensitivity of 1,3 β-D-glucan for common causes of candidaemia in South Africa. Mycoses. 2019 Aug 8. doi: 10.1111/myc.12982. [Epub ahead of print] PubMed [citation] PMID: 31393662
3. Della Pepa R, Cerchione C, Pugliese N, Colicchio R, Salvatore P, Sirignano C, Soscia E, Pagano L, Sanguinetti M, Pane F, Picardi M. Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3-β-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography. Support Care Cancer. 2018 Jun;26(6):1691-1694. doi: 10.1007/s00520-018-4138-9. Epub 2018 Mar 9. No abstract available. PubMed [citation] PMID: 29523967.
4. Dichtl K, Seybold U, Wagener J. Serological biomarkers of candidemia: a retrospective evaluation of three assays. Infection. 2019 Apr;47(2):217-224. doi: 10.1007/s15010-018-1224-3. Epub 2018 Sep 27. PubMed [citation] PMID: 30264200.
5. Farhour Z, Mehraj V, Chen J, Ramendra R, Lu H, Routy JP. Use of (1→3)-β-D-glucan for diagnosis and management of invasive mycoses in HIV-infected patients. Mycoses. 2018 Oct;61(10):718-722. doi: 10.1111/myc.12797. Epub 2018 Jul 5. Review. PubMed [citation] PMID: 29855088, PMCID: PMC6175469.
6. Fernández-Cruz A, Semiglia MA, Guinea J, Martínez-Jiménez MDC, Escibano P, Kwon M, Rodríguez-Macías G, Chamorro-de-Vega E, Rodríguez-González C, Navarro R, Galar A, Sánchez-Carrillo C, Díez-Martín JL, Muñoz P. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. Med Mycol. 2019 Jun 24. pii: myz060. doi: 10.1093/mmy/myz060. [Epub ahead of print] PubMed [citation] PMID: 31231772
8. Fernandez-Silva, F., et. al., (2013). Evaluation of the Efficacies of Amphotericin B, Posaconazole, Voriconazole and Anidulafungin in a Murine Disseminated Infection by the Emerging Opportunistic Fungus *Sarocladium (Acremonium) kiliense*. Antimicrob. Agents Chemother. 57: 6265-9.
9. Friedrich R, Rappold E, Bogdan C, Held J. Comparative Analysis of the Wako β-Glucan Test and the Fungitell® Assay for Diagnosis of Candidemia and *Pneumocystis jirovecii* Pneumonia. J Clin Microbiol. 2018 Aug 27;56(9). pii: e00464-18. doi: 10.1128/JCM.00464-18. Print 2018 Sep. PubMed [citation] PMID: 29899003, PMCID: PMC6113455.

10. Gianella S, Letendre SL, Iudicello J, Franklin D, Gaufin T, Zhang Y, Porrachia M, Vargas-Meneses M, Ellis RJ, Finkelman M, Hoenigl M. Plasma (1→3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. J Neurovirol. 2019 Jul 11. doi:10.1007/s13365-019-00775-6. [Epub ahead of print] PubMed [citation] PMID:31297727
11. Guitard J, Tabone MD, Senghor Y, Cros C, Moissenet D, Markowicz K, Valin N, Leverger G, Hennequin C. Detection of β-D-glucan for the diagnosis of invasive fungal infection in children with hematological malignancy. J Infect. 2016 Dec;73(6):607-615. doi: 10.1016/j.jinf.2016.07.007. Epub 2016 Jul 22. PubMed [citation] PMID: 27452196
12. Guitard J, Isnard F, Tabone MD, Antignac M, Brissot E, Senghor Y, Petit A, Leverger G, Hennequin C. Usefulness of β-D-glucan for diagnosis and follow-up of invasive candidiasis in onco-haematological patients. J Infect. 2018 May;76(5):483-488. doi: 10.1016/j.jinf.2018.01.011. Epub 2018 Feb 9. PubMed [citation] PMID: 29432826.
13. Hale, T.W., Bateman, T.L., Finkelman, M.A. and Berens, P.D., (2009). The absence of *Candida albicans* in milk samples of women with symptoms of ductal candidiasis. Breastfeeding Med. 4: 57-61.
14. Hartl B, Zeller I, Manhart A, Selitsch B, Lass-Flörl C, Willinger B. A Retrospective Assessment of Four Antigen Assays for the Detection of Invasive Candidiasis Among High-Risk Hospitalized Patients. Mycopathologia. 2018 Jun;183(3):513-519. doi: 10.1007/s11046-017-0238-1. Epub 2018 Jan 22. PubMed [citation] PMID: 29356937, PMCID: PMC5958149.
15. Hoenigl M, de Oliveira MF, Pérez-Santiago J, Zhang Y, Woods SP, Finkelman M, Gianella S. Correlation of (1→3)-β-D-glucan with other inflammation markers in chronically HIV infected persons on suppressive antiretroviral therapy. GMS Infect Dis. 2015;3. pii: Doc3. Epub 2015 Dec 22. PubMed [citation] PMID: 27917362, PMCID: PMC5132183
16. Hoenigl M, Pérez-Santiago J, Nakazawa M, de Oliveira MF, Zhang Y, Finkelman MA, Letendre S, Smith D, Gianella S. (1→3)-β-D-Glucan: A Biomarker for Microbial Translocation in Individuals with Acute or Early HIV Infection? Front Immunol. 2016 Oct 3;7:404. eCollection 2016. PubMed [citation] PMID: 27752257, PMCID: PMC5046804
17. Hoenigl M, de Oliveira MF, Pérez-Santiago J, Zhang Y, Morris S, McCutchan AJ, Finkelman M, Marcotte TD, Ellis RJ, Gianella S. (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study. Medicine (Baltimore). 2016 Mar;95(11):e3162. doi:10.1097/MD.0000000000003162. Erratum in: Medicine (Baltimore). 2016 May 20;95(20):e9582. PubMed [citation] PMID: 26986173, PMCID: PMC4839954
18. Hoenigl M, Moser C, Funderburg N, Bosch R, Kantor A, Zhang Y, Eugen-Olsen J, Finkelman M, Reiser J, Landay A, Moisi D, Lederman MM, Gianella S; ACTG NWCS 411 study team. Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression. Clin Infect Dis. 2018 Nov 12. doi: 10.1093/cid/ciy966. [Epub ahead of print] PubMed [citation] PMID: 30418519, PMCID: PMC6669298.
19. Kondori, N., Edebo, L., and Mattsby-Baltzer, I., (2004). Circulating (1→3)-β-D-glucan and Immunoglobulin G subclass antibodies to *Candida albicans* cell wall antigens in patients with systemic candidiasis. Clinical and diagnostic Laboratory Immunology. 11(2):344-350.
20. McKeating C, White PL, Posso R, Palmer M, Johnson E, McMullan R. Diagnostic accuracy of fungal PCR and β-D-glucan for detection of candidaemia: a preliminary evaluation. J Clin Pathol. 2018 May;71(5):420-424. doi: 10.1136/jclinpath-2017-204692. Epub 2017 Sep 28. PubMed [citation] PMID: 28970296.



Reference List Publish Date:  
September 2019

Corporate Headquarters  
Associates of Cape Cod, Inc.  
124 Bernard E. Saint Jean Drive  
East Falmouth, MA 02536 USA  
Tel: (508) 540-3444  
www.acciusa.com

United Kingdom  
Associates of Cape Cod Int'l., Inc.  
Deacon Park, Moorgate Road  
Knowsley, Liverpool L33 7RX  
United Kingdom  
Tel: (44) 151-547-7444  
www.acciuk.co.uk

Europe  
Associates of Cape Cod Europe, Inc.  
Opelstrasse 14  
D-64546 Mörfelden-Walldorf  
Germany  
Tel: (49) 61 05-96 10 0  
www.acciusa.de

Page 5  
MKT#19-018

# THE FUNGITELL® ASSAY REFERENCE LIST

Selected references for clinical, pre-clinical and basic research involving diagnostic (1→3)-β-D-glucanemia

21. Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, Kema I, Jenabian MA, Costiniuk C, Lebouché B, Thomas R, Coté P, LeBlanc R, Baril JG, Durand M, Chartrand-Lefebvre C, Tremblay C, Ancuta P, Bernard NF, Sheppard DC, Routy JP; Montreal Primary HIV-infection Study and Canadian HIV and Aging Cohort Study Groups. Circulating (1→3)-β-D-Glucan is associated with immune activation during HIV infection. Clin Infect Dis. 2019 Mar 16. pii: ciz212. doi: 10.1093/cid/ciz212. [Epub ahead of print] PubMed [citation] PMID: 30877304.
22. Mehraj V, Ramendra R, Isnard S, Dupuy FP, Lebouché B, Costiniuk C, Thomas R, Szabo J, Baril JG, Trottier B, Coté P, LeBlanc R, Durand M, Chartrand-Lefebvre C, Kema I, Zhang Y, Finkelman M, Tremblay C, Routy JP. CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection. Front Immunol. 2019 Feb 21;10:289. doi: 10.3389/fimmu.2019.00289. eCollection 2019. PubMed [citation] PMID: 30846990, PMCID: PMC6393370.
23. Mitchell, K.F. et al., (2013). Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-*albicans* *Candida* Biofilms. Antimicrob. Agents Chemother. 57: 1918-1920.
24. Myint T, Chow FC, Bloch KC, Raymond-Guillen L, Davis TE, Wright PW, Woc-Colburn L, Khairy RN, Street AC, Yamamoto T, Albers A, Wheat LJ, Hage CA. Detection of (1→3)-β-D-Glucan in Cerebrospinal Fluid in Histoplasma Meningitis. J Clin Microbiol. 2018 Sep 25;56(10). pii: e00663-18. doi: 10.1128/JCM.00663-18. Print 2018 Oct. PubMed [citation] PMID: 30021828, PMCID: PMC6156302.
25. Passos AIM, Dertkigil RP, Ramos MC, Busso-Lopes AF, Tararan C, Ribeiro EO, Schreiber AZ, Trabasso P, Resende MR, Moretti ML. Serum markers as an aid in the diagnosis of pulmonary fungal infections in AIDS patients. Braz J Infect Dis. 2017 Nov - Dec;21(6):606-612. doi: 10.1016/j.bjid.2017.07.002. Epub 2017 Jul 29. PubMed [citation] PMID: 28759746
26. Petraitiene, R., Petraitis, V., Hope, W.W., Mickiene, D., Kelaher, A.M., Murray, H.A., Mya-San, C., Hughes, J.E., Cotton, M.P., Bacher, J. and Walsh, T.J., (2008). CSF and Plasma (1→3)-β-D-glucan as surrogate markers for detection and therapeutic response of experimental hematogenous *Candida* meningoencephalitis. Antimicrobial Agents and Chemotherapy. 52: 4121-4129.
27. Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Grimaldi F, Zacheo I, Raimondo M, Sirignano C, Salvatore P, Pane F. (1→3)-β-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations. Ann Hematol. 2019 Feb;98(2):527-531. doi: 10.1007/s00277-018-3441-3. Epub 2018 Jul 23. No abstract available. PubMed [citation] PMID: 30033485.
28. Pini P, Colombari B, Marchi E, Castagnoli A, Venturelli C, Sarti M, Blasi E. Performance of *Candida albicans* germ tube antibodies (CAGTA) and its association with (1→3)-β-D-glucan (BDG) for diagnosis of invasive candidiasis (IC). Diagn Microbiol Infect Dis. 2019 Jan;93(1):39-43. doi: 10.1016/j.diagmicrobio.2018.07.007. Epub 2018 Aug 8. No abstract available. Erratum in: Diagn Microbiol Infect Dis. 2019 Jun;94(2):211. PubMed [citation] PMID: 30098849.
29. Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, Routy JP. Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation. Front Immunol. 2019 Mar 18;10:465. doi: 10.3389/fimmu.2019.00465. eCollection 2019. Review. PubMed [citation] PMID: 30967860, PMCID: PMC6430738
30. Sav. H., et al., (2012). The importance of bronchoalveolar lavage (BAL) sample for galactomannan, (1→3)-β-D-glucan and PCR tests. Mikrobiyol. Bul. 46: 695-701.
31. Schelenz S, Owens K, Guy R, Rautemaa-Richardson R, Manuel RJ, Richardson M, Moore C, Enoch DA, Micallef C, Howard P, Agrawal SG, Johnson EM, Muller-Pebody B; English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice. J Infect. 2019 Aug;79(2):167-173. doi: 10.1016/j.jinf.2019.06.009. Epub 2019 Jun 21. PubMed [citation] PMID: 31233810.
32. Shupp, J.W., Petraitiene, R., Jaskille, A.D., Pavlovich, A.R., Matt, S.E., Nguyen, D.T., Kath, M.A., Jeng, J.C., Jordan, M.H., Finkelman, M., Walsh, T.J., Shoham, S., (2011). Early serum (1→3)-β-D-glucan levels in patients with burn injury. Mycoses 55:224-7.
33. Singh S, Kaur H, Choudhary H, Sethi S, Malhotra P, Gupta KL, Rudramurthy SM, Chakrabarti A. Evaluation of biomarkers: Galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre. Indian J Med Microbiol. 2018 Oct-Dec;36(4):557-563. doi:10.4103/ijmm.IJMM\_18\_366. PubMed [citation] PMID: 30880706.
34. Talento AF, Dunne K, Joyce EA, Palmer M, Johnson E, White PL, Springer J, Loeffler J, Ryan T, Collins D, Rogers TR. A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit. J Crit Care. 2017 Aug;40:119-127. doi: 10.1016/j.jcrc.2017.03.025. Epub 2017 Mar 30. PubMed [citation] PMID: 28384600
35. Tasaka, S. and Tokuda, H., (2012). *Pneumocystis jirovecii* pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J. Infect. Chemother. 18(6):793-806.
36. Vargas, S.A., et al., (2013). Near-universal prevalence of *Pneumocystis* and associated increase in mucus in the lungs of infants with sudden unexpected death. Clin. Inf. Dis. 56: 171-179.

